NTP-CERHR monograph on the potential human reproductive and developmental effects of methylphenidate

    NTP CERHR MON
    |December 21, 2006
    PubMed

    Insights

    Methylphenidate (Ritalin) shows negligible concern for tics and minimal concern for growth restriction in children. However, data are insufficient to conclude on pregnancy loss or broader reproductive effects in humans.

    Area of Science:

    • Toxicology
    • Reproductive Health
    • Developmental Biology

    Background:

    • Methylphenidate is a widely prescribed central nervous system stimulant for ADHD and narcolepsy.
    • Public concern exists regarding its effects on child development.
    • The National Toxicology Program (NTP) Center for the Evaluation of Risks to Human Reproduction (CERHR) evaluated its reproductive and developmental toxicity.

    Purpose of the Study:

    • To assess the potential for methylphenidate to cause adverse effects on human reproduction and development.
    • To address public concerns regarding methylphenidate's impact on child development.

    Main Methods:

    • Comprehensive review of available developmental studies in children and experimental animals.
    • Evaluation of data by an Expert Panel.
    • Consideration of public comments on the findings.

    Main Results:

    • Negligible concern for methylphenidate-induced tics and movement disorders at therapeutic doses.
    • Minimal concern for methylphenidate-induced growth restriction, observed only at high doses in animal studies with reversible effects.
    • Insufficient data to conclude on associations with pregnancy loss or general reproductive effects in humans.

    Conclusions:

    • Methylphenidate poses low risk for tics and growth issues in children.
    • Further research is needed to determine reproductive risks in pregnant women and overall human reproductive safety.
    • NTP-CERHR monographs provide comprehensive risk evaluations for federal agencies and the public.

    Related Concept Videos

    Teratogenicity01:07

    Teratogenicity

    The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
    Attention-Deficit/Hyperactivity Disorder01:30

    Attention-Deficit/Hyperactivity Disorder

    Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
    Diagnostic Criteria and Symptoms
    To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
    CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

    CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

    CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
    Mutagenicity and Carcinogenicity01:25

    Mutagenicity and Carcinogenicity

    Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...